A paper on clinical research using our conditioned medium has been published in the Journal of Clinical Medicine.

It has been reported that systemic administration of conditioned medium (CM) derived from human adipose tissue (AD) and human umbilical cord (UC) tissue mesenchymal stromal cells (mesenchymal stem cells*; MSC) manufactured using our technology may alleviate symptoms in patients with chronic fatigue.

Chronic fatigue is seen in conditions such as post-COVID-19 syndrome and significantly impairs quality of life, but its cause is completely unknown, and no effective treatment has been established.
This time, the results of administration to patients with chronic fatigue using CM derived from AD- and UC-MSC (MSC-CM) manufactured using our technology were published in the peer-reviewed scientific journal, “Journal of Clinical Medicine”.

Like MSC, MSC-CM has been studied for its potential effectiveness against various intractable diseases.
In this observational study, 18 patients with chronic fatigue received systemic administration of MSC-CM intravenously three times at one-month intervals.
Additionally, one patient with chronic fatigue received inhalation administration 12 times at one-week intervals. No serious adverse events were observed in any of the patients. Furthermore, about half of the patients (10 out of 19) showed improvement in their subjective symptoms of chronic fatigue.
When comparing the serum levels of the inflammatory marker CRP (C Reactive Protein) before and after administration, it was observed that the CRP levels decreased in patients whose levels were higher than the reference value before administration.
This suggests that the anti-inflammatory action of the MSC-CM may improve chronic fatigue.

This paper is the first in the world to report on the potential of systemic administration of MSC-CM as a treatment for chronic fatigue, and the development of new treatments using MSC-CM is expected in the future.

*: In accordance with the statement dated June 6, 2025, by the Japanese Society for Regenerative Medicine, the term “mesenchymal stromal cells” is used instead of the conventional term “mesenchymal stem cells,” with the old term noted in parentheses.